







Results Review, 26 June 2014

REGIONAL

ont Initiation

Preview

Results

Strategy

Jodate

Hai-O (HAIO MK)

Consumer Non-cyclical - Household & Personal Products

Market Cap: USD154m

Neutral (Maintained)

Target Price: MYR2.73

Price: MYR2.53

In Transition



Source: Bloomberg

Avg Turnover (MYR/USD)	0.21m/0.06m
Cons. Upside (%)	18.6
Upside (%)	7.9
52-wk Price low/high (MYR)	2.39 - 2.82
Free float (%)	50
Share outstanding (m)	196
Shareholders (%)	
Tan Kai Hee	9.9
Akintan SB	7.7

Share Performance (%)

	YTD	1m	3m	6m	12m
Absolute	(1.6)	0.0	1.6	(1.9)	(8.0)
Relative	(2.8)	(1.1)	(1.3)	(4.8)	(10.1)

Ngo Siew Teng +603 9207 7660

ngo.siew.teng@rhbgroup.com

Hai-O's FY14 results were within consensus and our forecasts. Sales and core net profit were weaker, due to lower sales across the board. A final single-tier dividend of 10 sen per share was proposed this quarter. We adjust our FV to MYR2.73 from MYR2.60, as we roll over our valuation to CY15. Maintain NEUTRAL.

- ♦ FY14 numbers in line. Hai-O's FY14 revenue and core earnings (excluding a MYR4.8m gain from the disposal of vacant land, and a one-off MYR1.5m cost relating to the company's corporate social responsibility programs in FY13) dropped by 4.9% and 6.5% y-o-y respectively. The softer sales numbers were largely due to a 10.6% y-o-y revenue decline in the multi-level marketing (MLM) division, as the group revised its strategy to focus on small-ticket items instead of big-ticket ones. Turnover from its retail and "others" segments also moderated by 5.1% and 10.9% y-o-y, offsetting the slight revenue improvement in the wholesale division (+0.6% y-o-y). Core earnings were softer, no thanks to: i) weaker EBIT from the wholesale division (-33.9% y-o-y) due to the weakening of the MYR against the USD, and ii) poorer EBIT from the retail segment (-33.5% y-o-y) from higher operating expenses. Compared with 4QFY13, revenue and core earnings dropped by 14.9% and 5.3% y-o-y respectively due to weaker sales in the current quarter.
- ♦ Better margin for MLM. FY14 EBIT and PBT margins dropped 1.7 ppts and 3 ppts y-o-y respectively. The better EBIT margin from MLM (20.2% vs 17.8% y-o-y) was dragged down by the lower margins from the wholesale (9.3% vs 14.1% y-o-y), retail (5.8% vs 8.2% y-o-y) and "others" (38.9% vs 58.3% y-o-y) divisions.
- Key risks. Key investment risks are: i) a decline in consumer spending power, ii) intensifying competition, and iii) an inability to pass on higher costs to consumers
- Maintain NEUTRAL. We leave our earnings estimates untouched, given the in-line results. Our FV is revised to MYR2.73 from MYR2.60 as we roll over our valuation to 12x CY15 EPS from CY14. Maintain NEUTRAL, as the stock is currently trading close to its historical P/E of 12x.

Forecasts and Valuations	Apr-12	Apr-13	Apr-14	Apr-15F	Apr-16F
Total turnover (MYRm)	240	267	253	283	295
Reported net profit (MYRm)	32.1	47.2	40.5	44.7	45.8
Recurring net profit (MYRm)	31.3	43.3	40.5	44.7	45.8
Recurring net profit growth (%)	14.3	38.4	(6.5)	10.3	2.4
Recurring EPS (MYR)	0.15	0.21	0.20	0.22	0.23
DPS (MYR)	0.09	0.14	0.10	0.13	0.13
Recurring P/E (x)	16.4	11.8	12.7	11.5	11.2
P/B (x)	2.31	2.14	2.02	1.80	1.68
P/CF (x)	10.8	16.1	19.8	10.3	8.9
Dividend Yield (%)	3.6	5.5	4.0	5.0	5.2
EV/EBITDA (x)	8.03	6.28	7.24	6.24	6.05
Return on average equity (%)	15.1	20.5	16.4	16.6	15.5
Net debt to equity (%)	net cash				
Our vs consensus EPS (adjusted) (%)				(13.5)	(11.4)

Source: Company data, RHB estimates



Figure 1: Results review

FYE Apr (MYRm)	4QFY13	3QFY14	4QFY14	q-o-q (%)	у-о-у (%)	FY13	FY14	у-о-у (%)	Comments
Revenue	72.3	71.6	61.5	(14.2)	(14.9)	266.5	253.4	(4.9)	Lower due to weaker sales from MLM
EBITDA	16.3	14.5	12.9	(11.5)	(21.1)	61.9	55.0	(11.1)	
EBITDA Margin (%)	22.6	20.3	20.9			23.2	21.7		
Depreciation	(0.6)	(0.8)	(0.8)	(0.1)	38.9	(2.7)	(3.0)	11.9	
EBIT	15.8	13.8	12.1	(12.2)	(23.2)	59.2	52.0	(12.1)	
EBIT Margin (%)	21.8	19.2	19.7			22.2	20.5		
		45	(z)			()	45		
Interest expense	(0.1)	(0.1)	(0.1)	26.7	(22.1)	(0.6)	(0.4)	(34.8)	
Interest income	0.4	0.5	0.5	12.1	21.6	1.2	1.6	30.7	
Associates	(0.0)	(0.0)	(0.0)	nm	nm	0.2	(0.1)	nm	
EI/Others	(1.5)	0.0	0.0	nm	nm	3.9	0.0	nm	
Pretax profit	14.6	14.2	12.5	(11.5)	(14.0)	63.9	53.1	(16.9)	
Pretax Margin (%)	20.2	19.8	20.4			24.0	21.0		
Tax	(4.4)	(3.5)	(1.7)	(51.3)	(60.8)	(15.9)	(12.1)	(24.3)	
	` '	` '		(31.3)	(00.0)	, ,	` '	(24.3)	
Effective tax rate (%)	(30.1)	(24.9)	(13.7)			(24.9)	(22.7)		
Minority Interest	(0.4)	(0.2)	(0.1)			(0.9)	(0.6)		
Net Profit	9.8	10.4	10.7	2.8	9.2	47.2	40.5	(14.2)	In line with RHBRI's numbers
Core Profit	11.3	10.4	10.7	2.8	(5.3)	43.3	40.5	(6.5)	
Net Margin (%)	15.6	14.5	17.4			16.2	16.0		

Source: Company

Figure 2: Segmental breakdown

Revenue (MYRm)	4QFY13	3QFY14	4QFY14	q-o-q (%)	y-o-y (%)	FY13	FY14	у-о-у (%)	Comments
MLM	45.9	38.5	37.8	(1.9)	(17.7)	167.0	149.3	(10.6)	Due to strategy of focusing on small ticket items instead of big ticket items
Wholesale	35.6	46.4	33.7	(27.3)	(5.4)	137.9	138.7	0.6	3
Retail	12.7	13.3	9.2	(30.9)	(27.7)	42.2	40.1	(5.1)	
Others	4.4	5.0	3.9	(21.8)	(10.7)	18.4	16.4	(10.9)	
EBIT (MYRm)	4QFY13	3QFY14	4QFY14	q-o-q (%)	у-о-у (%)	FY13	FY14	у-о-у (%)	Comments
MLM	8.1	8.5	8.4	(1.4)	2.9	29.8	30.1	1.1	
Wholesale	3.3	3.0	1.3	(58.2)	(62.4)	19.5	12.9	(33.9)	
Retail	1.4	0.8	0.6	(26.7)	(57.2)	3.5	2.3	(33.5)	Due to higher operating expenses
Others	1.1	1.8	1.2	(33.9)	8.1	10.7	6.4	(40.5)	oxportooo

Source: Company

Figure 3: Assumptions

	FY15	FY16
CDF growth rate (%)	1	1

Source: Company data



Figure 4: HAIO's perfo FYE Apr (MYRm)	ormance for th 1QFY13	e past eigh 2QFY13	nt quarters 3QFY13	4QFY13	1QFY14	2QFY14	3QFY14	4QFY14
Revenue	54.7	65.3	68.3	72.3	54.7	65.6	71.6	61.5
Growth q-o-q (%)		19.4	4.6	5.8	-24.3	19.9	9.1	-14.1
Growth y-o-y					0.0	0.5	4.8	-14.9
EBITDA	12.4	15.7	15.6	16.3	12.3	15.4	14.5	12.9
EBITDA Margin (%)	22.7	24.0	22.8	22.6	22.5	23.5	20.3	20.9
Depreciation	(0.7)	(0.7)	(0.7)	(0.6)	(0.7)	(8.0)	(0.8)	(0.8)
EBIT	11.7	15.0	14.9	15.8	11.6	14.6	13.7	12.1
EBIT Margin (%)	21.4	23.0	21.8	21.8	21.2	22.3	19.1	19.7
Interest expense	(0.1)	(0.2)	0.3	(0.1)	(0.1)	(0.1)	0.5	(0.1)
Interest income	0.3	0.3	(0.2)	0.4	0.3	0.2	(0.1)	0.5
Associates	0.0	0.0	0.1	(0.0)	0.0	(0.1)	0.0	(0.0)
EI/Others	0.0	5.4	0.0	(1.5)	0.0	0.0	0.0	0.0
Pretax profit	11.9	20.5	15.1	14.6	11.8	14.6	14.1	12.5
Pretax Margin (%)	21.8	31.4	22.1	20.2	21.6	22.3	19.7	20.4
Tax	(3.1)	(4.0)	(4.1)	(4.4)	(3.1)	(3.7)	(3.5)	(1.7)
Effective tax rate (%)	25.7	19.5	27.2	30.1	26.3	25.3	24.8	13.7
Minority Interest	(0.1)	(0.4)	0.0	(0.4)	0.1	(0.4)	(0.2)	(0.1)
Net Profit	8.8	16.1	11.0	9.8	8.8	10.5	10.4	10.7

11.0

16.1

11.3

15.6

8.8

16.1

10.7

17.3

Net Margin (%)
Source: Company

Core Profit

Figure 5: Evolution of EBIT (%)

10.5

16.0

8.8

16.1



10.4

14.5

10.7

17.4

Source: Company data



Financial Exhibits

Profit & Loss (MYRm)	Apr-12	Apr-13	Apr-14	Apr-15F	Apr-16F
Total turnover	240	267	253	283	295
Cost of sales	(148)	(162)	(160)	(176)	(183)
Gross profit	91	104	94	107	111
Gen & admin expenses	(23)	(24)	(22)	(26)	(27)
Selling expenses	(26)	(29)	(26)	(31)	(32)
Other operating costs	4	9	6	10	10
Operating profit	46	60	52	60	62
Operating EBITDA	48	62	55	62	64
Depreciation of fixed assets	(2)	(2)	(3)	(2)	(2)
Operating EBIT	46	60	52	60	62
Interest income	1	1	2	-	-
Interest expense	(1)	(1)	(0)	(1)	(1)
Exceptional income - net	1	4	-	-	-
Pre-tax profit	47	64	53	60	61
Taxation	(13)	(16)	(12)	(15)	(16)
Minority interests	(2)	(1)	(1)	-	-
Profit after tax & minorities	32	47	41	45	46
Reported net profit	32	47	41	45	46
Recurring net profit	31	43	41	45	46

Source: Company data, RHB estimates

Cash flow (MYRm)	Apr-12	Apr-13	Apr-14	Apr-15F	Apr-16F
Operating profit	46	60	52	60	62
Depreciation & amortisation	2	2	3	2	2
Change in working capital	12	(7)	(11)	(9)	(2)
Other operating cash flow	1	(6)	(5)	10	10
Operating cash flow	60	49	39	64	72
Interest received	(1)	(1)	(2)	-	-
Interest paid	1	1	0	1	1
Dividends received	(2)	(2)	-	-	-
Tax paid	(11)	(15)	(12)	(15)	(16)
Cash flow from operations	47	32	26	50	58
Capex	-	(9)	(5)	(15)	(15)
Other new investments	(40)	(10)	(4)	18	-
Other investing cash flow	21	28	12	-	-
Cash flow from investing activities	(19)	9	2	3	(15)
Dividends paid	(15)	(26)	(20)	(25)	(27)
Shares repurchased	(2)	-	-	-	-
Increase in debt	(3)	0	(4)	7	-
Other financing cash flow	(1)	(4)	(10)	(11)	(11)
Cash flow from financing activities	(21)	(29)	(34)	(29)	(37)
Cash at beginning of period	46	54	65	60	88
Total cash generated	8	12	(6)	24	5
Forex effects	(0)	-	-	-	1
Implied cash at end of period	54	66	59	83	94

Source: Company data, RHB estimates



Financial Exhibits

Balance Sheet (MYRm)	Apr-12	Apr-13	Apr-14	Apr-15F	Apr-16F
Total cash and equivalents	54	65	60	88	94
Inventories	38	50	59	43	44
Accounts receivable	20	19	19	37	38
Other current assets	66	61	58	41	42
Total current assets	177	195	195	208	218
Total investments	47	44	41	30	30
Tangible fixed assets	62	65	65	92	105
Intangible assets	0	0	3	-	-
Total other assets	3	3	3	-	-
Total non-current assets	112	112	113	122	135
Total assets	290	306	308	330	353
Short-term debt	5	7	3	3	3
Accounts payable	32	35	33	26	28
Other current liabilities	12	7	4	4	4
Total current liabilities	50	49	39	33	34
Total long-term debt	8	6	3	10	10
Other liabilities	0	0	0	-	-
Total non-current liabilities	8	7	3	10	10
Total liabilities	58	56	42	43	44
Share capital	101	101	101	101	101
Retained earnings reserve	127	148	164	184	204
Other reserves	(6)	(10)	(11)	-	-
Shareholders' equity	222	240	254	285	305
Minority interests	10	11	12	2	4
Total equity	231	251	266	287	309
Total liabilities & equity	290	307	308	330	353


Source: Company data, RHB estimates


Key Ratios (MYR)	Apr-12	Apr-13	Apr-14	Apr-15F	Apr-16F
Revenue growth (%)	7.3	11.3	(4.9)	11.8	4.0
Operating profit growth (%)	18.1	30.5	(13.3)	16.1	3.0
Net profit growth (%)	17.3	47.1	(14.2)	10.3	2.4
EPS growth (%)	17.3	47.1	(14.2)	10.3	2.4
Bv per share growth (%)	8.5	8.1	6.1	12.1	7.1
Operating margin (%)	19.2	22.5	20.5	21.3	21.1
Net profit margin (%)	13.4	17.7	16.0	15.8	15.5
Return on average assets (%)	11.8	15.8	13.2	14.0	13.4
Return on average equity (%)	15.1	20.5	16.4	16.6	15.5
Net debt to equity (%)	(17.7)	(20.6)	(20.4)	(26.1)	(26.2)
DPS	0.09	0.14	0.10	0.13	0.13
Recurrent cash flow per share	0.23	0.16	0.13	0.24	0.28


Source: Company data, RHB estimates



SWOT Analysis







Source: Company data, RHB estimates

Source: Company data, RHB estimates

Company Profile

Hai-O is involved in wholesaling, retailing, multi-level marketing and pharmaceuticals. It also operates modern Chinese medicinal clinics.



Recommendation Chart



Source: RHB estimates, Bloomberg

Date	Recommendation	Target Price	Price
2014-03-27	Neutral	2.60	2.45
2013-12-19	Neutral	2.70	2.55
2013-07-23	Buy	3.28	2.71
2013-06-27	Buy	2.91	2.66
2013-03-28	Neutral	2.35	2.40
2012-06-29	Neutral	2.16	2.20
2012-04-20	Neutral	2.03	2.18
2012-03-30	Neutral	1.99	2.18

Source : RHB estimates, Bloomberg



RHB Guide to Investment Ratings

Buy: Share price may exceed 10% over the next 12 months

Trading Buy: Share price may exceed 15% over the next 3 months, however longer-term outlook remains uncertain

Neutral: Share price may fall within the range of +/- 10% over the next 12 months Take Profit: Target price has been attained. Look to accumulate at lower levels

Sell: Share price may fall by more than 10% over the next 12 months Not Rated: Stock is not within regular research coverage

Disclosure & Disclaimer

All research is based on material compiled from data considered to be reliable at the time of writing, but RHB does not make any representation or warranty, express or implied, as to its accuracy, completeness or correctness. No part of this report is to be construed as an offer or solicitation of an offer to transact any securities or financial instruments whether referred to herein or otherwise. This report is general in nature and has been prepared for information purposes only. It is intended for circulation to the clients of RHB and its related companies. Any recommendation contained in this report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific addressee. This report is for the information of addressees only and is not to be taken in substitution for the exercise of judgment by addressees, who should obtain separate legal or financial advice to independently evaluate the particular investments and strategies.

This report may further consist of, whether in whole or in part, summaries, research, compilations, extracts or analysis that has been prepared by RHB's strategic, joint venture and/or business partners. No representation or warranty (express or implied) is given as to the accuracy or completeness of such information and accordingly investors should make their own informed decisions before relying on the same.

RHB, its affiliates and related companies, their respective directors, associates, connected parties and/or employees may own or have positions in securities of the company(ies) covered in this research report or any securities related thereto, and may from time to time add to, or dispose off, or may be materially interested in any such securities. Further, RHB, its affiliates and related companies do and seek to do business with the company(ies) covered in this research report and may from time to time act as market maker or have assumed an underwriting commitment in securities of such company(ies), may sell them or buy them from customers on a principal basis and may also perform or seek to perform significant investment banking, advisory or underwriting services for or relating to such company(ies), as well as solicit such investment, advisory or other services from any entity mentioned in this research report.

RHB and its employees and/or agents do not accept any liability, be it directly, indirectly or consequential losses, loss of profits or damages that may arise from any reliance based on this report or further communication given in relation to this report, including where such losses, loss of profits or damages are alleged to have arisen due to the contents of such report or communication being perceived as defamatory in nature.

The term "RHB" shall denote where applicable, the relevant entity distributing the report in the particular jurisdiction mentioned specifically herein below and shall refer to RHB Research Institute Sdn Bhd, its holding company, affiliates, subsidiaries and related companies.

All Rights Reserved. This report is for the use of intended recipients only and may not be reproduced, distributed or published for any purpose without prior consent of RHB and RHB accepts no liability whatsoever for the actions of third parties in this respect.

Malaysia

This report is published and distributed in Malaysia by RHB Research Institute Sdn Bhd (233327-M), Level 11, Tower One, RHB Centre, Jalan Tun Razak, 50400 Kuala Lumpur, a wholly-owned subsidiary of RHB Investment Bank Berhad (RHBIB), which in turn is a wholly-owned subsidiary of RHB Capital Berhad.

Singapore

This report is published and distributed in Singapore by DMG & Partners Research Pte Ltd (Reg. No. 200808705N), a wholly-owned subsidiary of DMG & Partners Securities Pte Ltd, a joint venture between Deutsche Asia Pacific Holdings Pte Ltd (a subsidiary of Deutsche Bank Group) and OSK Investment Bank Berhad, Malaysia which have since merged into RHB Investment Bank Berhad (the merged entity is referred to as "RHBIB", which in turn is a wholly-owned subsidiary of RHB Capital Berhad). DMG & Partners Securities Pte Ltd is a Member of the Singapore Exchange Securities Trading Limited. DMG & Partners Securities Pte Ltd may have received compensation from the company covered in this report for its corporate finance or its dealing activities; this report is therefore classified as a non-independent report.

As of 24 June 2014, DMG & Partners Securities Pte Ltd and its subsidiaries, including DMG & Partners Research Pte Ltd do not have proprietary positions in the securities covered in this report, except for:

As of 24 June 2014, none of the analysts who covered the securities in this report has an interest in such securities, except for:

Special Distribution by RHB

Where the research report is produced by an RHB entity (excluding DMG & Partners Research Pte Ltd) and distributed in Singapore, it is only distributed to "Institutional Investors", "Expert Investors" or "Accredited Investors" as defined in the Securities and Futures Act, CAP. 289 of Singapore. If you are not an "Institutional Investor", "Expert Investor" or "Accredited Investor", this research report is not intended for you and you should disregard this research report in its entirety. In respect of any matters arising from, or in connection with this research report, you are to contact our Singapore Office, DMG & Partners Securities Pte Ltd

Hong Kong

This report is published and distributed in Hong Kong by RHB OSK Securities Hong Kong Limited ("RHBSHK") (formerly known as OSK Securities Hong Kong Limited), a subsidiary of OSK Investment Bank Berhad, Malaysia which have since merged into RHB Investment Bank Berhad (the merged entity is referred to as "RHBIB"), which in turn is a wholly-owned subsidiary of RHB Capital Berhad.



RHBSHK, RHBIB and/or other affiliates may beneficially own a total of 1% or more of any class of common equity securities of the subject company. RHBSHK, RHBIB and/or other affiliates may, within the past 12 months, have received compensation and/or within the next 3 months seek to obtain compensation for investment banking services from the subject company.

Risk Disclosure Statements

The prices of securities fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. Past performance is not a guide to future performance. RHBSHK does not maintain a predetermined schedule for publication of research and will not necessarily update this report

Indonesia

This report is published and distributed in Indonesia by PT RHB OSK Securities Indonesia (formerly known as PT OSK Nusadana Securities Indonesia), a subsidiary of OSK Investment Bank Berhad, Malaysia, which have since merged into RHB Investment Bank Berhad, which in turn is a wholly-owned subsidiary of RHB Capital Berhad.

Thailand

This report is published and distributed in Thailand by RHB OSK Securities (Thailand) PCL (formerly known as OSK Securities (Thailand) PCL), a subsidiary of OSK Investment Bank Berhad, Malaysia, which have since merged into RHB Investment Bank Berhad, which in turn is a wholly-owned subsidiary of RHB Capital Berhad.

Other Jurisdictions

In any other jurisdictions, this report is intended to be distributed to qualified, accredited and professional investors, in compliance with the law and regulations of the jurisdictions.

Kuala Lumpur Hong Kong Singapore

Malaysia Research Office

RHB Research Institute Sdn Bhd Level 11, Tower One, RHB Centre Jalan Tun Razak Kuala Lumpur Malaysia

Tel: +(60) 3 9280 2185 Fax: +(60) 3 9284 8693 RHB OSK Securities Hong Kong Ltd. (formerly known as OSK Securities

Hong Kong Ltd.)

12th Floor

World-Wide House

19 Des Voeux Road
Central, Hong Kong

Tel: +(852) 2525 1118 Fax: +(852) 2810 0908 Fax: +(65) 6532 6211

DMG & Partners

Securities Pte. Ltd.

10 Collyer Quay #09-08 Ocean Financial Centre

Singapore 049315

Tel: +(65) 6533 1818

Jakarta Shanghai Phnom Penh

PT RHB OSK Securities Indonesia (formerly known as PT OSK Nusadana

Securities Indonesia)
Plaza CIMB Niaga
14th Floor
Jl. Jend. Sudirman Kav.25
Jakarta Selatan 12920, Indonesia
Tel: +(6221) 2598 6888

Fax: +(6221) 2598 6777

RHB OSK (China) Investment Advisory Co. Ltd. (formerly known as OSK (China) Investment

Advisory Co. Ltd.)
Suite 4005, CITIC Square
1168 Nanjing West Road
Shanghai 20041
China

Tel: +(8621) 6288 9611 Fax: +(8621) 6288 9633 RHB OSK Indochina Securities Limited (formerly known as OSK Indochina Securities Limited)

No. 1-3, Street 271 Sangkat Toeuk Thla, Khan Sen Sok Phnom Penh Cambodia Tel: +(855) 23 969 161 Fax: +(855) 23 969 171

Bangkok

RHB OSK Securities (Thailand) PCL (formerly known

as OSK Securities (Thailand) PCL) 10th Floor, Sathorn Square Office Tower

oth Floor, Sathorn Square Office Tow 98, North Sathorn Road,Silom Bangrak, Bangkok 10500 Thailand Tel: +(66) 2 862 9999 Fax: +(66) 2 108 0999